These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12819516)
1. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. Louie M; Hogan C; Hurley A; Simon V; Chung C; Padte N; Lamy P; Flaherty J; Coakley D; Di Mascio M; Perelson AS; Markowitz M AIDS; 2003 May; 17(8):1151-6. PubMed ID: 12819516 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401 [TBL] [Abstract][Full Text] [Related]
3. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results. Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523 [TBL] [Abstract][Full Text] [Related]
5. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS; J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321. Della Negra M; De Carvalho AP; De Aquino MZ; Pinto JA; Da Silva MT; Andreatta KN; Graham B; Liu YP; Quirk EK Pediatr Infect Dis J; 2015 Apr; 34(4):398-405. PubMed ID: 25599284 [TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Squires K; Pozniak AL; Pierone G; Steinhart CR; Berger D; Bellos NC; Becker SL; Wulfsohn M; Miller MD; Toole JJ; Coakley DF; Cheng A; Ann Intern Med; 2003 Sep; 139(5 Pt 1):313-20. PubMed ID: 12965939 [TBL] [Abstract][Full Text] [Related]
8. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155 [TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K; Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703 [TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Fung HB; Stone EA; Piacenti FJ Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284 [TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS; AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866 [TBL] [Abstract][Full Text] [Related]
14. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Della Negra M; de Carvalho AP; de Aquino MZ; da Silva MT; Pinto J; White K; Arterburn S; Liu YP; Enejosa JV; Cheng AK; Chuck SL; Rhee MS Pediatr Infect Dis J; 2012 May; 31(5):469-73. PubMed ID: 22301477 [TBL] [Abstract][Full Text] [Related]
15. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study. Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472 [TBL] [Abstract][Full Text] [Related]